Finance ForgeBETA
Crear cuenta gratis
1)Empresas2)Rankings3)Iniciar sesión
Finance Forge Terminal v1.49.5
PrivacidadTérminosCookiesAviso Legal
● Connected
ENDV US Equity
ENDONOVO THERAPEUTICS, INC.
—USD
Healthcare
Biotechnology
96)Comparar97)Tesis →
Market Cap
$0
Shares Outstanding
1.8B
Revenue (TTM)
$255,723
Net Income (TTM)
−$4M
— Annual —FY2022
Revenue
$135,355
Gross Margin
92.6%
Operating Margin
-2411.7%
Net Margin
-13649.2%
ROCE
10.2%
Net Debt/EBITDA
-2.7×
Current Ratio
0
D/E Ratio
-0.22
Book Value / Share
-0.02
ENDV US Equity
—USD
Tesis →

ENDONOVO THERAPEUTICS, INC. (ENDV): análisis fundamental y valoración

Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud

Price History
Loading...
Perfil
BolsaOTCPaísUnited StatesBeta38.16Web↗ www.endonovo.com

Endonovo Therapeutics, Inc., a biotechnology company, engages in the development, manufacture, and distribution of non-invasive Electroceutical medical devices for regenerative medicine. The company offers SofPulse, a non-invasive Electroceutical therapeutic device for the palliative treatment of soft tissue injuries, …

Múltiplos de Valoración
P/E (Annual)
—
P/E (TTM)
—
P/FCF (Annual)
—
P/FCF (TTM)
—
EV/EBITDA
—
EV/Revenue
—
P/Sales
—
P/Book
—
Rentabilidad (Último Anual)
Gross Margin
92.6%
Operating Margin
-2411.7%
Net Margin
-13649.2%
FCF Margin
—
ROE
—
ROCE
10.2%
ROA
-1441.9%
Effective Tax Rate
0.0%
Métricas TTM
Revenue TTM
$255,723
Gross Profit TTM
$246,034
Operating Income TTM
−$3M
Net Income TTM
−$4M
FCF TTM
—
EPS TTM
—
Quarters Used
4
TTM Period
2022-12-31 → 2023-09-30
Solidez del Balance
Net Debt
$7M
Net Debt / EBITDA
-2.7×
Debt / Equity
-0.22
Current Ratio
0
Interest Coverage
—
Working Capital
−$33M
Book Value / Share
-0.02
Net Debt / Share
0
Crecimiento (YoY)
Revenue YoY
+85.2%
Net Income YoY
-495.0%
FCF YoY
—
EPS Diluted YoY
—
Retorno al Accionista
Dividend Yield
—
Payout Ratio
—
FCF / Share
—
CapEx % Revenue
—
Rev / Employee
—
Empresas similares
Smart Money
vs Sector: Healthcare (1130 empresas)
MétricaENDVMediana SectorΔ
Gross Margin92.6%57.0%+35.6%
Operating Margin-2411.7%-38.6%-2373.1%
Net Margin-13649.2%-33.6%-13615.6%
FCF Margin—-13.9%—
ROE—-40.4%—
ROA-1441.9%-32.0%-1409.9%
Current Ratio0.002.84-2.84
Debt / Equity-0.220.28-0.50
Scoring Fundamental
Piotroski F-Score
3/ 9Débil
✗F1ROA positivo (rentabilidad activos)
✗F2Flujo caja operativo positivo
✗F3ROA mejora vs año anterior
✓F4Calidad de beneficios (OCF > ROA)
✗F5Apalancamiento baja
✗F6Liquidez mejora (current ratio)
✗F7Sin dilución accionarial
✓F8Margen bruto mejora
✓F9Rotación activos mejora
Altman Z-ScoreZona de Riesgo
-121.63
x1_working_capital-26.041
x2_retained_earnings-58.629
x3_ebit-2.548
x4_market_equity0.000
x5_sales0.106
>2.99 segura · 1.81–2.99 gris · <1.81 riesgo
Capital Allocation
2/ 8Débil
✗FCF+Free cash flow positivo
✗FCFmMargen FCF > 10%
✗DilucSin dilución significativa (< 2%/año en 3 años)
✗Rev↑Revenue CAGR 3 años > 5%
✓ROCERetorno sobre capital empleado > 10%
✓DeudaDeuda neta/EBITDA < 3× (o posición de caja neta)
✗Mg↑Margen operativo ≥ hace 2-3 años (tolerancia -2pp)
✗Inv.R&D + Capex > 3% de revenue (reinversión en el negocio)
Histórico Piotroski F-Score
Histórico de Múltiplos